Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $2.0 million.

  • Arcus Biosciences' Depreciation & Amortization (CF) changed negligibly% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.0 million for FY2024, which is 25.00% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Depreciation & Amortization (CF) is $2.0 million, which was down 0.00% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Depreciation & Amortization (CF) ranged from a high of $3.0 million in Q4 2023 and a low of $800,000 during Q1 2021.
  • In the last 3 years, Arcus Biosciences' Depreciation & Amortization (CF) had a median value of $2.0 million in 2025 and averaged $2.3 million.
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' Depreciation & Amortization (CF) was 200.00% (2023), while the steepest drop was 50.00% (2023).
  • Over the past 5 years, Arcus Biosciences' Depreciation & Amortization (CF) (Quarterly) stood at $1.4 million in 2021, then declined by 29.43% to $1.0 million in 2022, then spiked by 200.00% to $3.0 million in 2023, then remained steady at $3.0 million in 2024, then remained steady at $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $3.0 million during Q1 2025.